Lifestyle intervention using mobile technology and smart devices in patients with high cardiovascular risk: A pragmatic randomised clinical trial

Antihypertensive effects of abalone viscera fermented with Lactiplantibacillus pentosus SN001 via angiotensin-converting enzyme inhibition

“…Cholesterol and triglycerides are important parameters in cardiovascular disease ( Tekkeşin et al, 2020 ). The unfermented group, in which rats consumed abalone viscera powder, tended to have higher levels of triglycerides in the blood, and total cholesterol was significantly higher than that in the control group.…”

Effect of a mobile application and smart devices on heart rate variability in diabetic patients with high cardiovascular risk: A sub-study of the LIGHT randomized clinical trial

“…Our study appears as an indicator of the modifiable structure of HRV with a healthy lifestyle in diabetic patients. Although diabetes mellitus results Adjusted for baseline HbA 1c , 1-year HbA 1c , baseline and 1-year anti-hypertensive and β-blocker Data were presented as mean (standard deviation [SD]) for normally distributed continuous variables Abbreviations: HF, high frequency; HRV, heart rate variability; LF, low frequency; pNN50, percentage of the differences between adjacent normal R-R intervals exceeding 50 milliseconds; RMSSD, square root of the mean squared difference of successive R-R intervals; SDANN index, standard deviation of the mean R-R intervals calculated over a 5-minute period; SDNN, standard deviation of normal to normal R-R intervals; SDNN index, mean of the standard deviation of R-R intervals calculated over a 5-minute period; TP, total power Mobile application systems have been found both beneficial and useful in previous trials regarding heart failure, atrial fibrillation, and primary prevention of cardiovascular diseases [12,14,15]. Moreover, these systems have presented trustworthy positive results in the self-management of diabetes mellitus [16].…”

“…This investigation was a sub-study of lifestyle intervention using mobile technology in patients with high cardiovascular risk: A pragmatic randomized clinical Trial (LIGHT) implemented in the tertiary cardiovascular center from February 2018 to March 2020 [12]. In the LIGHT trial, the participants, who were between 20 and 79 years of age and at high risk for cardiovascular diseases, as indicated by a 10-year atherosclerotic cardiovascular disease (ASCVD) risk score of ≥7.5%, were randomly allocated to either arm: the intervention plus usual care or usual care (NCT03397849).…”

The effect of 1-year mean step count on the change in the atherosclerotic cardiovascular disease risk calculation in patients with high cardiovascular risk: a sub-study of the LIGHT randomized clinical trial

“…Our study was a sub-study of the lifestyle intervention using mobile technology in patients with high cardiovascular risk: a pragmatic randomized clinical (LIGHT) trial conducted in a tertiary hospital between February 2018 and March 2020 [5] (NCT03397849). All patients were randomized into usual care or usual care plus the lifestyle intervention using mobile technology.…”